Does the media prefer HYFT or TENX?

In the previous week, MindWalk had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 2 mentions for MindWalk and 1 mentions for Tenax Therapeutics. MindWalk's average media sentiment score of 0.40 beat Tenax Therapeutics' score of 0.00 indicating that MindWalk is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SRZN or HYFT?

MindWalk has higher revenue and earnings than Surrozen. MindWalk is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 71.80 -$242.03M -$37.59 N/A MindWalk $17.59M 4.41 -$21.69M -$0.20 N/A

Is SRZN or HYFT more profitable?

MindWalk has a net margin of -66.79% compared to Surrozen's net margin of -4,810.50%. MindWalk's return on equity of -69.37% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% -4,055.04% -154.08% MindWalk -66.79% -69.37% -39.74%

Does the media prefer SRZN or HYFT?

In the previous week, MindWalk had 1 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for MindWalk and 1 mentions for Surrozen. MindWalk's average media sentiment score of 0.40 beat Surrozen's score of 0.00 indicating that MindWalk is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, NAGE or HYFT?

Niagen Bioscience has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Niagen Bioscience $129.42M 2.12 $17.38M $0.21 16.43 MindWalk $17.59M 4.41 -$21.69M -$0.20 N/A

Does the media refer more to NAGE or HYFT?

In the previous week, Niagen Bioscience had 3 more articles in the media than MindWalk. MarketBeat recorded 5 mentions for Niagen Bioscience and 2 mentions for MindWalk. MindWalk's average media sentiment score of 0.40 beat Niagen Bioscience's score of 0.08 indicating that MindWalk is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, AMRN or HYFT?

MindWalk has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.37 -$38.80M -$0.65 N/A MindWalk $17.59M 4.41 -$21.69M -$0.20 N/A

Is AMRN or HYFT more profitable?

Amarin has a net margin of -15.51% compared to MindWalk's net margin of -66.79%. Amarin's return on equity of -2.99% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% MindWalk -66.79% -69.37% -39.74%

Does the media refer more to AMRN or HYFT?

In the previous week, Amarin had 2 more articles in the media than MindWalk. MarketBeat recorded 4 mentions for Amarin and 2 mentions for MindWalk. Amarin's average media sentiment score of 0.75 beat MindWalk's score of 0.40 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ELDN or HYFT?

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 2 mentions for MindWalk. MindWalk's average media sentiment score of 0.40 beat Eledon Pharmaceuticals' score of 0.20 indicating that MindWalk is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MindWalk (HYFT) Competitors

$1.68 -0.17 (-9.19%)

Closing price 04:00 PM Eastern

Extended Trading

$1.73 +0.05 (+2.98%)

As of 07:44 PM Eastern

Compare

HYFT vs. TENX, SRZN, NAGE, AMRN, and ELDN

Should you buy MindWalk stock or one of its competitors? MarketBeat compares MindWalk with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MindWalk include Tenax Therapeutics (TENX), Surrozen (SRZN), Niagen Bioscience (NAGE), Amarin (AMRN), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry.

How does MindWalk compare to Tenax Therapeutics?

MindWalk (NASDAQ:HYFT) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

MindWalk has higher revenue and earnings than Tenax Therapeutics. MindWalk is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	4.41	-$21.69M	-$0.20	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

MindWalk presently has a consensus target price of $5.00, suggesting a potential upside of 197.62%. Tenax Therapeutics has a consensus target price of $29.67, suggesting a potential upside of 176.48%. Given MindWalk's higher probable upside, equities analysts plainly believe MindWalk is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, MindWalk had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 2 mentions for MindWalk and 1 mentions for Tenax Therapeutics. MindWalk's average media sentiment score of 0.40 beat Tenax Therapeutics' score of 0.00 indicating that MindWalk is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Tenax Therapeutics' return on equity of -56.32% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Tenax Therapeutics	N/A	-56.32%	-53.12%

6.7% of MindWalk shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 3.1% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MindWalk has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Summary

MindWalk beats Tenax Therapeutics on 9 of the 14 factors compared between the two stocks.

How does MindWalk compare to Surrozen?

Surrozen (NASDAQ:SRZN) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

MindWalk has higher revenue and earnings than Surrozen. MindWalk is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	71.80	-$242.03M	-$37.59	N/A
MindWalk	$17.59M	4.41	-$21.69M	-$0.20	N/A

In the previous week, MindWalk had 1 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for MindWalk and 1 mentions for Surrozen. MindWalk's average media sentiment score of 0.40 beat Surrozen's score of 0.00 indicating that MindWalk is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

MindWalk has a net margin of -66.79% compared to Surrozen's net margin of -4,810.50%. MindWalk's return on equity of -69.37% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
MindWalk	-66.79%	-69.37%	-39.74%

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Surrozen presently has a consensus price target of $42.00, indicating a potential upside of 95.17%. MindWalk has a consensus price target of $5.00, indicating a potential upside of 197.62%. Given MindWalk's higher possible upside, analysts plainly believe MindWalk is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

MindWalk beats Surrozen on 10 of the 15 factors compared between the two stocks.

How does MindWalk compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Niagen Bioscience has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.12	$17.38M	$0.21	16.43
MindWalk	$17.59M	4.41	-$21.69M	-$0.20	N/A

In the previous week, Niagen Bioscience had 3 more articles in the media than MindWalk. MarketBeat recorded 5 mentions for Niagen Bioscience and 2 mentions for MindWalk. MindWalk's average media sentiment score of 0.40 beat Niagen Bioscience's score of 0.08 indicating that MindWalk is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Niagen Bioscience has a net margin of 14.29% compared to MindWalk's net margin of -66.79%. Niagen Bioscience's return on equity of 22.68% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
MindWalk	-66.79%	-69.37%	-39.74%

Niagen Bioscience currently has a consensus target price of $14.67, suggesting a potential upside of 325.12%. MindWalk has a consensus target price of $5.00, suggesting a potential upside of 197.62%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities research analysts clearly believe Niagen Bioscience is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Niagen Bioscience has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Summary

Niagen Bioscience beats MindWalk on 13 of the 16 factors compared between the two stocks.

How does MindWalk compare to Amarin?

Amarin (NASDAQ:AMRN) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Amarin has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

In the previous week, Amarin had 2 more articles in the media than MindWalk. MarketBeat recorded 4 mentions for Amarin and 2 mentions for MindWalk. Amarin's average media sentiment score of 0.75 beat MindWalk's score of 0.40 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MindWalk has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.37	-$38.80M	-$0.65	N/A
MindWalk	$17.59M	4.41	-$21.69M	-$0.20	N/A

Amarin has a net margin of -15.51% compared to MindWalk's net margin of -66.79%. Amarin's return on equity of -2.99% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
MindWalk	-66.79%	-69.37%	-39.74%

Amarin currently has a consensus price target of $12.00, suggesting a potential downside of 13.85%. MindWalk has a consensus price target of $5.00, suggesting a potential upside of 197.62%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

22.3% of Amarin shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 6.8% of MindWalk shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amarin and MindWalk tied by winning 8 of the 16 factors compared between the two stocks.

How does MindWalk compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 2 mentions for MindWalk. MindWalk's average media sentiment score of 0.40 beat Eledon Pharmaceuticals' score of 0.20 indicating that MindWalk is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eledon Pharmaceuticals presently has a consensus price target of $9.67, suggesting a potential upside of 183.48%. MindWalk has a consensus price target of $5.00, suggesting a potential upside of 197.62%. Given MindWalk's stronger consensus rating and higher probable upside, analysts plainly believe MindWalk is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

MindWalk has higher revenue and earnings than Eledon Pharmaceuticals. MindWalk is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
MindWalk	$17.59M	4.41	-$21.69M	-$0.20	N/A

Eledon Pharmaceuticals has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
MindWalk	-66.79%	-69.37%	-39.74%

Summary

MindWalk beats Eledon Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get MindWalk News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYFT vs. The Competition

Export

Metric	MindWalk	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$85.39M	$988.58M	$4.24B	$11.97B
Dividend Yield	N/A	4.84%	7.93%	5.32%
P/E Ratio	N/A	1.49	21.75	23.66
Price / Sales	4.41	127.11	213.09	86.29
Price / Cash	N/A	20.06	53.68	55.53
Price / Book	4.54	7.92	27.92	6.39
Net Income	-$21.69M	-$4.04M	$109.80M	$337.36M
7 Day Performance	-4.55%	-2.79%	-3.42%	-3.07%
1 Month Performance	34.40%	66.23%	1.21%	0.37%
1 Year Performance	N/A	110.65%	12.95%	27.87%

MindWalk Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYFT MindWalk	3.1926 of 5 stars	$1.68 -9.2%	$5.00 +197.6%	N/A	$85.39M	$17.59M	N/A	80
TENX Tenax Therapeutics	2.8337 of 5 stars	$11.69 -1.6%	$29.67 +153.8%	+89.2%	$315.12M	N/A	N/A	9	News Coverage
SRZN Surrozen	4.0231 of 5 stars	$26.16 -1.1%	$42.00 +60.6%	+193.4%	$307.21M	$3.48M	N/A	80
NAGE Niagen Bioscience	4.4648 of 5 stars	$3.84 +0.3%	$14.67 +281.9%	-70.1%	$305.04M	$129.42M	18.29	120
AMRN Amarin	1.4107 of 5 stars	$14.41 -0.8%	$12.00 -16.7%	+16.5%	$304.47M	$213.65M	N/A	360	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYFT) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MindWalk (HYFT) Competitors

HYFT vs. TENX, SRZN, NAGE, AMRN, and ELDN

How does MindWalk compare to Tenax Therapeutics?

Summary

How does MindWalk compare to Surrozen?

Summary

How does MindWalk compare to Niagen Bioscience?

Summary

How does MindWalk compare to Amarin?

Summary

How does MindWalk compare to Eledon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MindWalk (HYFT) Competitors

HYFT vs. TENX, SRZN, NAGE, AMRN, and ELDN

How does MindWalk compare to Tenax Therapeutics?

Which has higher earnings and valuation, HYFT or TENX?

Do analysts prefer HYFT or TENX?

Does the media prefer HYFT or TENX?

Is HYFT or TENX more profitable?

Do institutionals & insiders have more ownership in HYFT or TENX?

Which has more risk & volatility, HYFT or TENX?

Summary

How does MindWalk compare to Surrozen?

Which has higher valuation & earnings, SRZN or HYFT?

Does the media prefer SRZN or HYFT?

Which has more risk & volatility, SRZN or HYFT?

Is SRZN or HYFT more profitable?

Do institutionals and insiders have more ownership in SRZN or HYFT?

Do analysts recommend SRZN or HYFT?

Summary

How does MindWalk compare to Niagen Bioscience?

Which has better valuation and earnings, NAGE or HYFT?

Does the media refer more to NAGE or HYFT?

Do institutionals and insiders hold more shares of NAGE or HYFT?

Is NAGE or HYFT more profitable?

Do analysts prefer NAGE or HYFT?

Which has more risk and volatility, NAGE or HYFT?

Summary

How does MindWalk compare to Amarin?

Which has more risk and volatility, AMRN or HYFT?

Does the media refer more to AMRN or HYFT?

Which has higher earnings and valuation, AMRN or HYFT?

Is AMRN or HYFT more profitable?

Do analysts recommend AMRN or HYFT?

Do insiders and institutionals hold more shares of AMRN or HYFT?

Summary

How does MindWalk compare to Eledon Pharmaceuticals?

Does the media favor ELDN or HYFT?

Which has more volatility & risk, ELDN or HYFT?

Do insiders and institutionals have more ownership in ELDN or HYFT?

Do analysts recommend ELDN or HYFT?

Which has better valuation and earnings, ELDN or HYFT?

Is ELDN or HYFT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools